GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Cyclically Adjusted PS Ratio

Champions Oncology (Champions Oncology) Cyclically Adjusted PS Ratio : 1.65 (As of May. 31, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Cyclically Adjusted PS Ratio?

As of today (2024-05-31), Champions Oncology's current share price is $4.53. Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $2.75. Champions Oncology's Cyclically Adjusted PS Ratio for today is 1.65.

The historical rank and industry rank for Champions Oncology's Cyclically Adjusted PS Ratio or its related term are showing as below:

CSBR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.84   Med: 3.31   Max: 11.4
Current: 1.64

During the past years, Champions Oncology's highest Cyclically Adjusted PS Ratio was 11.40. The lowest was 0.84. And the median was 3.31.

CSBR's Cyclically Adjusted PS Ratio is ranked better than
76.98% of 504 companies
in the Biotechnology industry
Industry Median: 5.425 vs CSBR: 1.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Champions Oncology's adjusted revenue per share data for the three months ended in Jan. 2024 was $0.884. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.75 for the trailing ten years ended in Jan. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Champions Oncology Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Champions Oncology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Cyclically Adjusted PS Ratio Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.60 3.81 5.12 3.21 1.85

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.85 2.41 1.99 2.11

Competitive Comparison of Champions Oncology's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted PS Ratio falls into.



Champions Oncology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Champions Oncology's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.53/2.75
=1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Champions Oncology's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0.884/130.1244*130.1244
=0.884

Current CPI (Jan. 2024) = 130.1244.

Champions Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.441 100.023 0.574
201407 0.328 100.520 0.425
201410 0.333 100.176 0.433
201501 0.326 98.604 0.430
201504 0.365 99.824 0.476
201507 0.324 100.691 0.419
201510 0.341 100.346 0.442
201601 0.293 99.957 0.381
201604 0.327 100.947 0.422
201607 0.373 101.524 0.478
201610 0.406 101.988 0.518
201701 0.325 102.456 0.413
201704 0.301 103.167 0.380
201707 0.458 103.278 0.577
201710 0.474 104.070 0.593
201801 0.462 104.578 0.575
201804 0.447 105.708 0.550
201807 0.493 106.324 0.603
201810 0.477 106.695 0.582
201901 0.559 106.200 0.685
201904 0.527 107.818 0.636
201907 0.580 108.250 0.697
201910 0.588 108.577 0.705
202001 0.659 108.841 0.788
202004 0.687 108.173 0.826
202007 0.671 109.318 0.799
202010 0.672 109.861 0.796
202101 0.745 110.364 0.878
202104 0.716 112.673 0.827
202107 0.840 115.183 0.949
202110 0.810 116.696 0.903
202201 0.917 118.619 1.006
202204 0.913 121.978 0.974
202207 1.016 125.002 1.058
202210 1.056 125.734 1.093
202301 0.942 126.223 0.971
202304 0.963 127.992 0.979
202307 0.930 128.974 0.938
202310 0.857 129.810 0.859
202401 0.884 130.124 0.884

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Champions Oncology  (NAS:CSBR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Champions Oncology Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093